Bupropion

證據等級: L5

預測適應症: 10 個

Bupropion: From Depression & Smoking Cessation to Attention Deficit-Hyperactivity Disorder

One-Sentence Summary

Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) originally developed for major depressive disorder and smoking cessation, with a mechanism uniquely distinct from serotonergic antidepressants. The TxGNN model predicts it may be effective for Attention Deficit-Hyperactivity Disorder (ADHD), with 8 clinical trials and 19 publications currently supporting this direction. The mechanistic rationale is strong — Bupropion directly targets the dopamine and norepinephrine deficits that are central to ADHD pathophysiology — and the evidence base includes a dedicated Cochrane review and multiple network meta-analyses in major journals.

Quick Overview

Item	Content
Original Indication	Major depressive disorder; smoking cessation (not currently registered in India)
Predicted New Indication	Attention Deficit-Hyperactivity Disorder (ADHD)
TxGNN Prediction Score	99.99%
Evidence Level	L1
India Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that blocks the dopamine transporter (DAT) and norepinephrine transporter (NET), raising synaptic concentrations of both catecholamines in the prefrontal cortex. Unlike most antidepressants, it has no serotonergic activity. This mechanism was the original basis for its antidepressant effects and its efficacy in smoking cessation (where dopaminergic reward pathways play a central role).

The core neurobiology of ADHD involves insufficient dopaminergic and noradrenergic signaling in prefrontal cortical circuits — precisely the same systems Bupropion modulates. This makes the mechanistic link direct and pharmacologically coherent, rather than speculative. Bupropion’s NDRI profile is complementary to first-line stimulants (methylphenidate, amphetamines), which also act via catecholamine enhancement. Importantly, Bupropion has no abuse potential, making it particularly valuable for ADHD patients with comorbid substance use disorders — a subpopulation underserved by stimulant therapy.

The clinical evidence reinforces this mechanistic rationale. A dedicated Cochrane review (PMID 28965364), two network meta-analyses published in The Lancet Psychiatry, and several completed Phase 2/3/4 trials specifically evaluating Bupropion for ADHD collectively place this prediction at evidence level L1. Bupropion already appears in clinical guidelines in multiple countries as a second-line non-stimulant agent for adult ADHD.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00048360	Phase 3	Completed	162	8-week multicenter double-blind RCT comparing Bupropion XR 300–450 mg/day vs. placebo in adults with ADHD; primary evaluation of efficacy, safety, and health outcomes — the strongest direct evidence for this indication
NCT00061087	Phase 2/3	Completed	115	RCT treating adult ADHD in patients on methadone maintenance; demonstrates efficacy in ADHD with concurrent opioid dependence, supporting use in comorbid populations
NCT00936299	Phase 4	Completed	105	Post-marketing study of Bupropion for ADHD in adolescents with comorbid substance use disorders; provides real-world safety and tolerability data in a younger, higher-risk group
NCT01270555	—	Completed	32	Open-label study of Bupropion SR for ADHD in adults with recent or current substance use disorders; tolerability focus; sample size limits generalisability
NCT00000268	—	Completed	32	Evaluated cocaine abuse and ADHD co-occurrence; ADHD treatment was a secondary outcome; indirect supporting evidence

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30097390	2018	Network Meta-Analysis	The Lancet Psychiatry	Comparative efficacy and tolerability of ADHD medications across all age groups; Bupropion included in head-to-head comparisons with stimulants and atomoxetine
33085721	2020	Systematic Review & Meta-Analysis	PLoS One	Comprehensive network meta-analysis of pharmacological treatments for adult ADHD; quantifies relative benefits and safety signals including Bupropion
40203844	2025	Large-Cohort Safety Study	The Lancet Psychiatry	Network meta-analysis comparing cardiovascular safety (haemodynamics, ECG) of ADHD medications in children, adolescents, and adults; directly relevant to clinical monitoring
28965364	2017	Cochrane Systematic Review	Cochrane Database of Systematic Reviews	Dedicated Cochrane review of Bupropion for ADHD in adults; evaluates efficacy and tolerability as a stimulant alternative; foundational evidence document
27813651	2017	Systematic Review	Journal of Child and Adolescent Psychopharmacology	Systematic review of Bupropion for ADHD specifically in children and adolescents; shows promising signals but notes the smaller evidence base versus the adult population
38950507	2024	Bayesian Network Meta-Analysis	Journal of Psychiatric Research	Evaluated efficacy and safety of monoamine reuptake inhibitors (including Bupropion) for ADHD across 31 clinical trials; positions Bupropion within the non-stimulant class
37405312	2023	Narrative Review	Health Psychology Research	Reviews pharmacokinetics, pharmacodynamics, and clinical mechanisms of Bupropion across depression, ADHD, and smoking cessation; useful cross-indication mechanistic bridge
38915262	2024	Clinical Review	Expert Review of Neurotherapeutics	Reviews current non-stimulant medications for adult ADHD; explicitly covers Bupropion for patients with inadequate response or poor tolerability to stimulants
26693882	2016	Systematic Review	Expert Review of Neurotherapeutics	Systematic review of alternative pharmacological strategies for adult ADHD; covers long-term data gaps and positions Bupropion relative to methylphenidate and atomoxetine
20051220	2010	Meta-Analysis	The Journal of Clinical Psychiatry	Estimates effect sizes for medications used to treat adult ADHD; enables indirect comparison of Bupropion efficacy with stimulants and other non-stimulants

India Market Information

Bupropion currently has no registered products in India (0 licenses on file). Any clinical development or market access initiative for the ADHD indication would require a new drug application or import/manufacturing licence through the Central Drugs Standard Control Organisation (CDSCO).

Safety Considerations

Drug Interactions (665 total interactions documented):

The following are the most clinically significant interactions identified, prioritised by severity:

Interacting Drug	Level	Clinical Note
Fentanyl	Major	Risk of serotonergic toxicity and CNS/respiratory depression
Tramadol	Major	Significantly increased seizure risk; serotonergic potentiation
Codeine	Major	CYP2D6 inhibition by Bupropion alters codeine-to-morphine conversion
Dihydrocodeine	Major	Same CYP2D6-mediated interaction as Codeine
Alfentanil	Major	CNS and respiratory depression potentiation
Methylphenidate	Major	Additive cardiovascular and CNS stimulant effects; clinically important given co-prescribing in ADHD management
Hydrocortisone	Major	May lower seizure threshold
Amantadine	Major	Increased risk of CNS toxicity, psychosis, and seizures
Aldesleukin	Major	Potentiation of CNS adverse effects
Lidocaine	Major	CYP-mediated pharmacokinetic interaction; cardiac conduction concerns
Ethanol	Moderate	Increased seizure risk; patients should be counselled to minimise alcohol use
Alprazolam	Moderate	CNS depression potentiation

For complete warnings and contraindications (including the seizure threshold concern that is central to Bupropion safety), please refer to the approved prescribing information or package insert. This data was not available in the current Evidence Pack and represents a blocking gap for formal safety assessment.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The combination of a directly plausible NDRI mechanism, multiple completed Phase 2/3/4 RCTs, a dedicated Cochrane systematic review, and high-quality network meta-analyses in The Lancet Psychiatry places this repurposing candidate at Level L1 evidence — the highest tier. Bupropion is already used off-label (and in guidelines) for adult ADHD in several countries; the primary barrier in India is the absence of any registered product rather than a lack of evidence.

To proceed, the following is needed:

Obtain the full prescribing information (SmPC/package insert): The absence of key warnings and contraindications is a blocking data gap. Of particular importance is Bupropion’s known dose-dependent seizure risk, which must be characterised before safety assessment can proceed.
File for CDSCO registration: As Bupropion has no current India marketing authorisation, a new drug application (NDA) or import licence application is a prerequisite for any clinical or commercial use.
Clarify target population: Evidence is strongest for adults with ADHD; for adolescents or patients with comorbid substance use disorders, tailored risk-benefit analyses and additional monitoring protocols are needed.
Review CYP2D6 interaction risks in the ADHD context: Given that Bupropion is a potent CYP2D6 inhibitor and may be co-prescribed with stimulants (e.g., methylphenidate) or other CNS-active agents in ADHD management, a formal drug interaction review specific to this population is warranted.
Obtain formal MOA documentation from DrugBank: To complete the mechanistic evidence package and support regulatory submissions.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.